NC
BCLI

NewSquare Capital’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

NewSquare Capital’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5
Closed -$144 – 625
2023
Q2 		$144 Hold
5
– – ﹤0.01% 775
2023
Q1 		$231 Hold
5
– – ﹤0.01% 781
2022
Q4 		$115 Buy
+5
New +$187 ﹤0.01% 764

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 22.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

NewSquare Capital's BCLI Position: Q3 2023 in Review

NewSquare Capital sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2023, closing a stake of 5 shares — an estimated $144 sold.

NewSquare Capital first reported a position in BCLI in Q4 2022 and held it in 3 quarters. The position peaked at $231 in Q1 2023. 53 funds tracked by Wall St. Rank hold BCLI as of Q3 2023.

  • NewSquare Capital reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 5 BRAINSTORM CELL THERAPUTC shares in Q3 2023, an estimated $144.
  • NewSquare Capital first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2022 and held it in 3 quarters.
  • NewSquare Capital's BRAINSTORM CELL THERAPUTC position peaked at $231 in Q1 2023.
  • 53 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.